Comments on: Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics

Comments on: Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics https://9krapalm.com/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969-achieving-first-clinical-milestone-in-collaboration-with-hygtia-therapeutics/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Wed, 17 Jun 2026 13:42:03 +0000 hourly 1 https://wordpress.org/?v=7.0.2